{"id":287,"date":"2026-06-03T19:00:00","date_gmt":"2026-06-03T19:00:00","guid":{"rendered":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/"},"modified":"2026-06-04T18:43:04","modified_gmt":"2026-06-04T18:43:04","slug":"cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies","status":"publish","type":"post","link":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/","title":{"rendered":"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<div class=\"td-post-featured-image\">\n<figure><img decoding=\"async\" width=\"696\" height=\"464\" class=\"entry-thumb td-modal-image\" src=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1-696x464.jpg\" srcset=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1-696x464.jpg 696w, https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg 1392w\" sizes=\"(-webkit-min-device-pixel-ratio: 2) 1392px, (min-resolution: 192dpi) 1392px, 696px\" alt=\"lab scientists\" title=\"Getty-2228269170\"\/><figcaption class=\"wp-caption-text\">Credit score: Jackyenjoyphotography\/Getty Pictures<\/p>\n<\/figcaption><\/figure>\n<\/div>\n<p>IDMO Cellares and TScan Therapeutics will work collectively to guage automated scientific manufacturing of TSC-101, which is TScan\u2019s lead TCR-T remedy candidate for sufferers with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).<\/p>\n<p>TSC-101 is designed to deal with residual illness and forestall relapse in sufferers with AML and MDS present process allogeneic hematopoietic cell transplantation (allo-HCT). The remedy candidate makes use of a gene modification strategy to engineer T cells from a wholesome donor right into a patient-specific cell remedy product. As TScan advances TSC-101 towards a pivotal trial, which is predicted to start within the second quarter of 2026, the corporate is evaluating Cellares\u2019 automated manufacturing platform as a scalable and economical path to future business demand.<\/p>\n<p>Beneath the settlement, Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle, its end-to-end manufacturing platform, and the Cell Q, its automated high quality management and launch testing system. These closed-system, absolutely automated workflows are designed to scale back course of variability, reduce labor depth, and allow constant execution throughout runs and geographies, in accordance with a Cellares official.<\/p>\n<p>\u201cAs we put together for the initiation of our pivotal research of TSC-101 this quarter, we&#8217;re growing our efforts for business readiness. Establishing a scalable and cost-efficient manufacturing technique is a vital element. Cellares\u2019 absolutely automated Cell Shuttle platform represents a promising strategy to automating and scaling cell remedy manufacturing, with the potential to scale back handbook processes and remove capability constraints,\u201d mentioned Ray Lockard, chief manufacturing and high quality officer of TScan Therapeutics.<\/p>\n<p>\u201cVia this analysis, we purpose to find out how this know-how may strengthen our long-term manufacturing community and assist broader affected person entry, supporting our purpose of delivering transformative therapies to sufferers as effectively and reliably as potential.\u201d<\/p>\n<p>\u201cSufferers with AML or MDS who stay susceptible to relapse following transplant characterize precisely the sort of underserved inhabitants that automated manufacturing was designed to achieve,\u201d added Fabian Gerlinghaus, co-founder and CEO of Cellares. \u201cBringing automation to a late-stage program like TSC-101, with its wholesome donor-derived however patient-specific manufacturing mannequin, is the sort of problem the Cell Shuttle and Cell Q have been constructed for, and we consider it represents the manufacturing economics any developer might want to attain a inhabitants of this scale.\u201d<\/p>\n<p>The settlement provides TCR-engineered T cell therapies to Cellares\u2019 portfolio of automated cell remedy modalities, which incorporates CAR T cell therapies, hematopoietic stem cell packages, and autologous progenitor T cell therapies.<\/p>\n<p>\u00a0<\/p>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.genengnews.com\/topics\/cancer\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Credit score: Jackyenjoyphotography\/Getty Pictures IDMO Cellares and TScan Therapeutics will work collectively to guage automated scientific manufacturing of TSC-101, which is TScan\u2019s lead TCR-T remedy candidate for sufferers with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). TSC-101 is designed to deal with residual illness and forestall relapse in sufferers with AML and MDS present [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":289,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[466,468,464,467,472,473,469,471,470,465],"class_list":["post-287","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-agree","tag-automated","tag-cellares","tag-evaluate","tag-hematologic","tag-malignancies","tag-manufacturing","tag-patients","tag-tsc101","tag-tscan"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies - Future News 24<\/title>\n<meta name=\"description\" content=\"Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T19:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T18:43:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies\",\"datePublished\":\"2026-06-03T19:00:00+00:00\",\"dateModified\":\"2026-06-04T18:43:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/\"},\"wordCount\":433,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/GettyImages-2228269170-1.jpg\",\"keywords\":[\"Agree\",\"Automated\",\"Cellares\",\"Evaluate\",\"Hematologic\",\"Malignancies\",\"Manufacturing\",\"Patients\",\"TSC101\",\"TScan\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/\",\"name\":\"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/GettyImages-2228269170-1.jpg\",\"datePublished\":\"2026-06-03T19:00:00+00:00\",\"dateModified\":\"2026-06-04T18:43:04+00:00\",\"description\":\"Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/GettyImages-2228269170-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/GettyImages-2228269170-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies - Future News 24","description":"Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/","og_locale":"en_US","og_type":"article","og_title":"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies - Future News 24","og_description":"Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/","og_site_name":"Future News 24","article_published_time":"2026-06-03T19:00:00+00:00","article_modified_time":"2026-06-04T18:43:04+00:00","og_image":[{"url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies","datePublished":"2026-06-03T19:00:00+00:00","dateModified":"2026-06-04T18:43:04+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/"},"wordCount":433,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg","keywords":["Agree","Automated","Cellares","Evaluate","Hematologic","Malignancies","Manufacturing","Patients","TSC101","TScan"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/","name":"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg","datePublished":"2026-06-03T19:00:00+00:00","dateModified":"2026-06-04T18:43:04+00:00","description":"Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#primaryimage","url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg","contentUrl":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/GettyImages-2228269170-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/cellares-and-tscan-agree-to-evaluate-automated-manufacturing-tsc-101-for-patients-with-hematologic-malignancies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Cellares and TScan Conform to Consider Automated Manufacturing TSC-101 for Sufferers with Hematologic Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=287"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/287\/revisions"}],"predecessor-version":[{"id":288,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/287\/revisions\/288"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/289"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}